<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82269</article-id><article-id pub-id-type="doi">10.7554/eLife.82269</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Hepatic inactivation of murine <italic>Surf4</italic> results in marked reduction in plasma cholesterol</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-288145"><name><surname>Tang</surname><given-names>Vi T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6079-9756</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288134"><name><surname>McCormick</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-288395"><name><surname>Xu</surname><given-names>Bolin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-288396"><name><surname>Wang</surname><given-names>Yawei</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-288397"><name><surname>Fang</surname><given-names>Huan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-288398"><name><surname>Wang</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288135"><name><surname>Siemieniak</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288150"><name><surname>Khoriaty</surname><given-names>Rami</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-113059"><name><surname>Emmer</surname><given-names>Brian T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7365-1021</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-53951"><name><surname>Chen</surname><given-names>Xiao-Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4564-5120</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1090"><name><surname>Ginsburg</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6436-8942</contrib-id><email>ginsburg@umich.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Life Sciences Institute, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>College of Future Technology, Peking University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>Center for Life Sciences, Peking University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>State Key Laboratory of Membrane Biology, Peking University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Internal Medicine, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Cell and Developmental Biology, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Human Genetics, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Pediatrics and Communicable Diseases, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schekman</surname><given-names>Randy</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Akhmanova</surname><given-names>Anna</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04pp8hn57</institution-id><institution>Utrecht University</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>04</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e82269</elocation-id><history><date date-type="received" iso-8601-date="2022-08-09"><day>09</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-03"><day>03</day><month>10</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-08-03"><day>03</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.01.502222"/></event></pub-history><permissions><copyright-statement>© 2022, Tang et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Tang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-82269-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-82269-figures-v2.pdf"/><related-article related-article-type="article-reference" ext-link-type="doi" xlink:href="10.7554/elife.38839" id="ra1"/><abstract><p>PCSK9 negatively regulates low-density lipoprotein receptor (LDLR) abundance on the cell surface, leading to decreased hepatic clearance of LDL particles and increased levels of plasma cholesterol. We previously identified SURF4 as a cargo receptor that facilitates PCSK9 secretion in HEK293T cells (Emmer et al., 2018). Here, we generated hepatic SURF4-deficient mice (<italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic>) to investigate the physiologic role of SURF4 in vivo. <italic>Surf4</italic><sup><italic>fl/fl</italic></sup> <italic>Alb-Cre</italic><sup><italic>+</italic></sup> mice exhibited normal viability, gross development, and fertility. Plasma PCSK9 levels were reduced by ~60% in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice, with a corresponding ~50% increase in steady state LDLR protein abundance in the liver, consistent with SURF4 functioning as a cargo receptor for PCSK9. Surprisingly, these mice exhibited a marked reduction in plasma cholesterol and triglyceride levels out of proportion to the partial increase in hepatic LDLR abundance. Detailed characterization of lipoprotein metabolism in these mice instead revealed a severe defect in hepatic lipoprotein secretion, consistent with prior reports of SURF4 also promoting the secretion of apolipoprotein B (APOB). Despite a small increase in liver mass and lipid content, histologic evaluation revealed no evidence of steatohepatitis or fibrosis in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. Acute depletion of hepatic SURF4 by CRISPR/Cas9 or liver-targeted siRNA in adult mice confirms these findings. Together, these data support the physiologic significance of SURF4 in the hepatic secretion of PCSK9 and APOB-containing lipoproteins and its potential as a therapeutic target in atherosclerotic cardiovascular diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>secretion</kwd><kwd>SURF4</kwd><kwd>PCSK9</kwd><kwd>APOB</kwd><kwd>cholesterol</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>20PRE35210706</award-id><principal-award-recipient><name><surname>Tang</surname><given-names>Vi T</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35HL135793</award-id><principal-award-recipient><name><surname>Ginsburg</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HL148333</award-id><principal-award-recipient><name><surname>Khoriaty</surname><given-names>Rami</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HL157062</award-id><principal-award-recipient><name><surname>Khoriaty</surname><given-names>Rami</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K08HL148552</award-id><principal-award-recipient><name><surname>Emmer</surname><given-names>Brian T</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2018YFA0506900</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Xiao-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>National Science Foundation of China</institution></institution-wrap></funding-source><award-id>91954001</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Xiao-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>National Science Foundation of China</institution></institution-wrap></funding-source><award-id>31571213</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Xiao-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>National Science Foundation of China</institution></institution-wrap></funding-source><award-id>31521062</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Xiao-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007270</institution-id><institution>University of Michigan</institution></institution-wrap></funding-source><award-id>Rackham Predoctoral Fellowship</award-id><principal-award-recipient><name><surname>Tang</surname><given-names>Vi T</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ginsburg</surname><given-names>David</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Inactivation of SURF4 leads to impaired secretion of PCSK9 and apolipoproteins resulting in low plasma cholesterol without detrimental consequences to the liver.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>An elevated plasma level of low-density lipoprotein (LDL) is a major risk factor for atherosclerotic cardiovascular disease (<xref ref-type="bibr" rid="bib6">Chapman et al., 2011</xref>), which is the leading cause of death worldwide. LDL is derived in the circulation by processing of very-low-density lipoprotein (VLDL) particles, which is synthesized and secreted by the liver. In humans, the major protein component of VLDL is APOB100, which is cotranslationally lipidated in the endoplasmic reticulum (ER) (<xref ref-type="bibr" rid="bib20">Kolovou et al., 2015</xref>). LDL is cleared from circulation by the LDL receptor (LDLR) on cell surfaces. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that is secreted by the liver and negatively regulates LDLR abundance by inducing its degradation (<xref ref-type="bibr" rid="bib3">Benjannet et al., 2004</xref>).</p><p>Proteins destined for extracellular secretion are transported from the endoplasmic reticulum (ER) to Golgi by COPII coated vesicles/tubules (<xref ref-type="bibr" rid="bib4">Bonifacino and Glick, 2004</xref>; <xref ref-type="bibr" rid="bib30">Palade, 1975</xref>). SEC24 is a key component of the COPII inner coat, which appears to play a primary role in selecting cargo proteins for export from the ER (<xref ref-type="bibr" rid="bib26">Miller et al., 2002</xref>). The mammalian genome encodes 4 paralogs of <italic>Sec24</italic> (<italic>Sec24a-d</italic>) (<xref ref-type="bibr" rid="bib40">Wendeler et al., 2007</xref>). Mice genetically deficient in SEC24A exhibit moderate hypocholesterolemia due to a selective block in PCSK9 secretion from the ER, resulting in an ~50% reduction in plasma PCSK9 levels (<xref ref-type="bibr" rid="bib7">Chen et al., 2013</xref>).</p><p>We previously reported a whole genome CRISPR screen in HEK293T cells heterologously expressing PCSK9, identifying Surfeit locus protein 4 (SURF4) as the putative cargo receptor potentially linking PCSK9 within the ER lumen to SEC24A on the cytoplasmic face of the ER membrane (<xref ref-type="bibr" rid="bib11">Emmer et al., 2018</xref>). SURF4 is a 29 kDa protein with multiple transmembrane domains that localizes to the ER and ER-Golgi intermediate compartment (ERGIC) (<xref ref-type="bibr" rid="bib27">Mitrovic et al., 2008</xref>). SURF4 is a homolog of Erv29p<italic>,</italic> a well-characterized cargo receptor in yeast that mediates the ER to Golgi trafficking of pro-α-mating factor (<xref ref-type="bibr" rid="bib2">Belden and Barlowe, 2001</xref>). The SURF4 ortholog in <italic>C. elegans</italic>, SFT-4, controls the ER export of the yolk protein VIT-2 (<xref ref-type="bibr" rid="bib34">Saegusa et al., 2018</xref>). Recent studies in human cells have also implicated SURF4 in the trafficking of other cargoes, including apolipoprotein B (APOB) (<xref ref-type="bibr" rid="bib12">Emmer et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Saegusa et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>), erythropoietin (EPO) (<xref ref-type="bibr" rid="bib23">Lin et al., 2020</xref>), growth hormone, dentin sialophosphoprotein, and amelogenin (<xref ref-type="bibr" rid="bib42">Yin et al., 2018</xref>). A role for SURF4 in APOB secretion was further supported by a recent study in which acute deletion of hepatic <italic>Surf4</italic> in adult mice caused hypocholesterolemia and a reduction in hepatic lipoprotein secretion (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>).</p><p>To investigate the physiologic significance of SURF4 in the secretion of PCSK9 and other putative cargoes, we previously generated mice with germline deletion of <italic>Surf4</italic>, which resulted in early embryonic lethality (<xref ref-type="bibr" rid="bib12">Emmer et al., 2020</xref>). We now report the generation and characterization of mice with <italic>Surf4</italic> selectively inactivated in the liver by combining a conditional <italic>Surf4</italic> allele (<italic>Surf4<sup>fl</sup></italic>) with a Cre recombinase expressed under the control of the albumin promoter (<italic>Alb-Cre</italic>). <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice exhibit normal development, survival and fertility, with marked plasma hypocholesterolemia associated with a hepatic secretion defect for PCSK9 and APOB-containing lipoproteins without evidence for liver injury. Acute inactivation of hepatic <italic>Surf4</italic> by CRISPR/Cas9 or liver-targeted siRNA in adult mice further confirms these findings and the potential of hepatic SURF4 as a therapeutic target in atherosclerotic cardiovascular disease.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Liver-specific deletion of <italic>Surf4</italic> is compatible with normal development and survival in mice</title><p>To investigate long term <italic>Surf4</italic> inactivation in hepatocytes in vivo, we generated mice with the <italic>Surf4</italic> gene genetically inactivated specifically in the liver by combining a previously reported conditional <italic>Surf4</italic> allele (in which <italic>Surf4</italic> exon 2 is flanked by loxP sites, denoted <italic>Surf4<sup>fl</sup></italic>) (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>) with a <italic>Cre</italic> recombinase transgene under control of the <italic>Albumin</italic> promoter (<italic>Alb-Cre</italic>). <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice were observed at the expected Mendelian ratio (<xref ref-type="table" rid="table1">Table 1</xref>). Both male and female <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice are fertile and produce offspring of the predicted genotypes at expected Mendelian ratios (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Genotype distribution of offspring of <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic>and <italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>-</sup></italic> intercrosses.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Genotype(Expected)</th><th align="left" valign="bottom"><italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>-</sup></italic>(25%)</th><th align="left" valign="bottom"><italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>+</sup></italic>(25%)</th><th align="left" valign="bottom"><italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic>(25%)</th><th align="left" valign="bottom"><italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic>(25%)</th><th align="left" valign="bottom"><italic>p</italic> (χ<sup>2</sup>)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Mating</td><td align="left" valign="bottom" colspan="4">♂ <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> X ♀ <italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>+</sup></italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">61<break/>(25.8%)</td><td align="char" char="." valign="bottom">71<break/>(30.1%)</td><td align="char" char="." valign="bottom">60<break/>(25.4%)</td><td align="char" char="." valign="bottom">44<break/>(18.6%)</td><td align="char" char="." valign="bottom">0.096</td></tr><tr><td align="left" valign="bottom">Mating</td><td align="left" valign="bottom" colspan="4">♂ <italic>Surf4<sup>fl/+</sup> Alb Cre <sup>-</sup></italic> X ♀ <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8<break/>(18.6%)</td><td align="char" char="." valign="bottom">9<break/>(20.9%)</td><td align="char" char="." valign="bottom">12<break/>(27.9%)</td><td align="char" char="." valign="bottom">14<break/>(32.6%)</td><td align="char" char="." valign="bottom">0.549</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>Excision of exon 2 is predicted to result in a frameshift mutation and the generation of a premature termination codon 8 base pairs downstream of the new exon1-3 junction (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Analysis of genomic DNA collected from mouse tails and livers of <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice demonstrated efficient Cre-mediated excision of <italic>Surf4</italic> exon 2 only in the liver (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), with the level of exon 2 containing <italic>Surf4</italic> transcripts in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice reduced to ~5% of controls (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This residual unexcised <italic>Surf4</italic> mRNA is likely derived from nonhepatocyte cell types in the liver. Quantitative PCR of liver cDNA using primers outside of exon 2 demonstrated a 38% reduction in total <italic>Surf4</italic> mRNA transcript in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice compared to <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> littermates, likely due to nonsense mediated mRNA decay (<xref ref-type="bibr" rid="bib32">Popp and Maquat, 2013</xref>). Analysis of <italic>Surf4</italic> mRNA transcripts by RNA sequencing confirmed the expected reduction of reads spanning the exon 1–2 and exon 2–3 junctions in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice compared to controls (150 and 148 vs 2,623 and 2490 reads, respectively, <xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Consistent with the qPCR data and incomplete nonsense mediated mRNA decay, we identified 928±51 reads mapping to the exon1-exon3 junction of the <italic>Surf4</italic> mRNA in liver from <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice and zero in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> samples (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This residual exon 2 excised mRNA in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> liver contains a premature stop codon near the start of the SURF4 coding sequence (codon 23 of 270), which is expected to be translated into a nonfunctional, truncated protein (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Generation of hepatocyte-specific <italic>Surf4</italic> deficient mice.</title><p>(<bold>A</bold>) Schematic presentation of the <italic>Surf4</italic> conditional allele. Blue rectangles represent exons and black line segments represent introns. Red triangles denote loxP sites. Expression of a <italic>Cre</italic> recombinase leads to excision of exon 2, which results in the generation of a <italic>Surf4</italic> mRNA lacking exon 2 (<italic>Surf4ΔE2</italic>) or both exon 2 and 3 (<italic>Surf4ΔE2-3</italic>). <italic>Surf4ΔE2</italic> mRNA is translated into a truncated SURF4 that is only 22 amino acids in length. <italic>Surf4ΔE2-3</italic> mRNA restores the reading frame, producing an internally truncated protein missing the 88 amino acids encoded by exon 2 and 3. P1, P2, P3 indicate the positions for <italic>Surf4</italic> genotyping primers (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Dashed arcs represent splicing events. Exons and introns are not drawn to scale. (<bold>B</bold>) Agarose gel electrophoresis of PCR products generated using genomic DNA (gDNA) isolated from mouse tails and livers and primers P1-3 shown in (<bold>A</bold>) (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). For <italic>Surf4</italic> genotyping, the wild type allele produces a smaller PCR product whereas the conditional allele produces a larger amplicon. Excision of exon 2 results in the generation of a PCR product of intermediate size (white arrowhead) that is present in gDNA isolated from the livers of <italic>Alb-Cre<sup>+</sup></italic> mice only. For <italic>Alb-Cre</italic> genotyping, presence of the <italic>Cre</italic> transgene results in a smaller PCR product. The upper band represents the amplification of an internal control (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). (<bold>C</bold>) Quantification of normalized (Norm.) <italic>Surf4</italic> mRNA abundance by quantitative PCR of liver cDNA from control (<italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic>) and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (n=4 per genotype). Crossbars represent the mean normalized abundance in each group. The denoted p-values were calculated by two-sided Student’s t-test. (<bold>D</bold>) Density plots of RNA-seq reads mapping along exons and exon-exon junctions of <italic>Surf4</italic> mRNA. <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice have lower overall read counts due to incomplete nonsense mediated mRNA decay. Arcs between exons represent splicing events and line thickness is proportional to read count. Exact read count for each junction is presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Uncropped and unedited gel shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-82269-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Read counts mapping to exon-exon junctions along the <italic>Surf4</italic> transcript based on RNA-sequencing data.</title><p>n=3 per genotype. Crossbars represent the mean read count in each sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig1-figsupp1-v2.tif"/></fig></fig-group><p>We also detected 404±39 reads (none in controls) mapping to the exon1-4 junction of an alternatively spliced <italic>Surf4</italic> mRNA in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Exclusion of exon 2 and 3 is predicted to restore the reading frame and result in the production of an internally deleted SURF4, missing ~1/3 of the full length sequence (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Though also likely to be nonfunctional, residual activity and/or a dominant-negative effect of this internally deleted SURF4 cannot be excluded.</p></sec><sec id="s2-2"><title>Reduced circulating PCSK9 and increased LDLR levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice</title><p>We previously demonstrated a key role of SURF4 in the efficient trafficking of PCSK9 heterologously expressed in HEK293T cells (<xref ref-type="bibr" rid="bib11">Emmer et al., 2018</xref>). To test the dependence of PCSK9 secretion on SURF4 in vivo, we first examined steady state serum PCSK9 levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> control mice. Serum PCSK9 levels are reduced by ∼60% in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice compared to <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> mice (from 46.0±19.0 ng/mL to 17.8±6.42 ng/mL, <xref ref-type="fig" rid="fig2">Figure 2A</xref>), although PCSK9 accumulation was not observed in liver lysates (<xref ref-type="fig" rid="fig2">Figure 2B–C</xref>). Quantitative RT-PCR revealed that <italic>Pcsk9</italic> mRNA levels were also unchanged (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), consistent with a defect in PCSK9 protein secretion rather than gene expression as the cause for decreased plasma PCSK9 levels.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Deletion of hepatic <italic>Surf4</italic> results in decreased serum PCSK9 level and profound hypocholesterolemia in mice.</title><p>(<bold>A</bold>) Serum PCSK9 levels measured by ELISA in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> littermate controls (n=6 per genotype). (<bold>B</bold>) Immunoblot for PCSK9 and HSP90 (loading control) in liver lysates collected from control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (n=4 per genotype) (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). (<bold>C</bold>) Quantification of liver PCSK9 levels presented in (<bold>B</bold>) (n=4 per genotype). (<bold>D</bold>) Serum PCSK9 levels in mice in which hepatic <italic>Surf4</italic> was acutely inactivated by CRISPR/Cas9 (n=4 per group). (<bold>E</bold>) Immunoblot of liver lysates collected from control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (n=4 per genotype) for LDLR and GAPDH (loading control) (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). (<bold>F</bold>) Quantification of liver LDLR levels presented in (<bold>E</bold>). (<bold>G</bold>) Steady-state plasma cholesterol levels in 2 months old control (<italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic>), heterozygous (<italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>+</sup></italic>), and homozygous (<italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic>) <italic>Surf4</italic> deleted mice. (<bold>H</bold>) Fractionation of lipoproteins in mouse serum by fast protein liquid chromatography (FPLC). Cholesterol and triglyceride levels were measured in each fraction. Each control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> sample was pooled from sera of 5 mice. Fractions corresponding to VLDL, LDL, and HDL are annotated. Crossbars represent the mean in all plots. For comparisons between control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic>, p-values were calculated by two-sided Student’s t-test. For comparison between control, heterozygous, and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup> mice</italic>, p-values were obtained by one-way ANOVA test followed by Tukey’s post hoc test. Molecular weight markers notated are in kDa.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Uncropped and unedited blots shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-82269-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Normalized (Norm) <italic>Pcsk9</italic> mRNA levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic>.and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice.</title><p>n=4 per genotype. Crossbars represent the mean, p-values were obtained from a two-sided Student’s t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Hepatic <italic>Surf4</italic> inactiavtion does not affect body mass while hypocholestrolemia is sustained through at least 1 year of age.</title><p>(<bold>A</bold>) Body mass of control (<italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic>), heterozygous (<italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>+</sup></italic>), and homozygous (<italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic>) mice at 2 months of age (n=6 per genotype). p-value was obtained by a one-way ANOVA test. (<bold>B–C</bold>) Serum cholesterol and body mass of 1-year-old control (n=8) and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. p-values were obtained from a two-sided Student’s t-test. For all panels: crossbars represent the mean.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig2-figsupp2-v2.tif"/></fig></fig-group><p>In contrast to the above findings, Wang et al reported no change in plasma PCSK9 levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (<xref ref-type="bibr" rid="bib38">Wang et al., 2021a</xref>). To address this issue, and to exclude complex adaptation to hepatic SURF4 deletion induced in utero, we acutely inactivated hepatic <italic>Surf4</italic> in adult mice using a previously reported Cas9 mouse system (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>). Analyses utilizing three different <italic>Surf4</italic> targeting sgRNAs demonstrated a reproducible ~40% reduction in plasma PCSK9 levels for all mice receiving <italic>Surf4</italic> targeting sgRNA compared to controls (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), consistent with our findings in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice.</p><p>Since PCSK9 is a negative regulator of LDLR, we next quantified LDLR levels in liver lysates collected from control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. As shown in <xref ref-type="fig" rid="fig2">Figure 2E–F</xref>, <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice exhibit an ~1.5-fold increase in LDLR abundance in liver lysates compared to controls, consistent with the observed ~60% reduction in circulating PCSK9 level.</p></sec><sec id="s2-3"><title>Marked reduction of plasma cholesterol in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice</title><p>Humans with heterozygous loss of function mutations in <italic>PCSK9</italic> exhibit an ~28–40% reduction in circulating cholesterol (<xref ref-type="bibr" rid="bib8">Cohen et al., 2005</xref>; <xref ref-type="bibr" rid="bib9">Cohen and Hobbs, 2013</xref>; <xref ref-type="bibr" rid="bib18">Hooper et al., 2007</xref>) with a similar reduction observed in <italic>Pcsk9<sup>+/-</sup></italic> mice (<xref ref-type="bibr" rid="bib33">Rashid et al., 2005</xref>). Though <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice exhibit similar reductions in PCSK9, total serum cholesterol is markedly reduced (from 54.3±15.1 mg/dL in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> mice to 9.51±2.6 mg/dL in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice) (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). No change in cholesterol was observed in the limited numbers of mice haploinsufficient for <italic>Surf4</italic> in the liver (<italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>+</sup></italic>). Analysis of fractionated pooled sera demonstrated marked reductions in cholesterol and triglyceride content in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice among all three major classes of lipoproteins – very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). This striking hypocholesterolemia phenotype is sustained through at least 1 year of age (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), with no difference in body mass between <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>).</p><p>Consistent with a role of SURF4 in the ER export of APOB-containing lipoproteins (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>), the mean serum APOB level in fasted <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice was 3.88±2.63 mg/mL, a&gt;98% reduction compared to <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> mice (300±157 mg/mL, <xref ref-type="fig" rid="fig3">Figure 3A</xref>). Western blotting demonstrated a trend towards an accumulation of APOB in the livers of <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice compared to littermate controls, predominantly in an endoglycosidase H (endo H) sensitive form (<xref ref-type="fig" rid="fig3">Figure 3B–C</xref>), indicative of ER retention (<xref ref-type="bibr" rid="bib14">Freeze and Kranz, 2010</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Hepatic lipoprotein and APOB secretion defect in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice.</title><p>(<bold>A</bold>) Steady-state serum APOB levels in control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice at 2 months of age (n=4 per genotype). (<bold>B</bold>) Representative immunoblot for APOB and HSP90 in liver lysates with and without endoglycosidase H (endo H) treatment. Proteins in the pre-Golgi compartments are expected to be sensitive to endo H cleavage, resulting in an electrophoretic shift on an immunoblot. Blue arrowhead indicates the endo H resistant band whereas the red arrowhead indicates the endo H sensitive band. Molecular weight markers notated are in kDa. Accumulation of endo H sensitive APOB in the absence of SURF4 suggests accumulation in the ER (<xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). (<bold>C</bold>) Quantification of APOB abundance in control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> liver lysates, without endo H treatment (n=4 per genotype). For panel A and C, crossbars represent the mean, with statistical significance determined by two-sided Student’s t-test. (<bold>D–G</bold>) <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> and littermate control mice were injected with a lipoprotein lipase inhibitor to block triglyceride hydrolysis. Blood was sampled prior to and following injection over 24 hr and assayed for (<bold>D</bold>) glucose, (<bold>E</bold>) cholesterol, (<bold>F</bold>) triglycerides, and (<bold>G</bold>) APOB levels. Data are presented as mean ± SEM for each time point (n=5 per genotype). Asterisks denote p&lt;0.05 obtained from two-sided Student’s t-test with Benjamini-Hochberg adjustment for multiple hypothesis testing, n.s., not significant.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Uncropped and unedited blots shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-82269-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig3-v2.tif"/></fig><p>We next examined hepatic triglyceride secretion in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> and control mice. For this experiment, mice were fasted to remove intestinal absorption of dietary fat and tissue lipid uptake was blocked by administration of a lipoprotein lipase inhibitor, with liver triglyceride output subsequently monitored by sampling of plasma triglycerides over 24 hours. Following fasting and inhibition of triglyceride hydrolysis, blood glucose levels fell equivalently between <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> littermates (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Although serum cholesterol and triglyceride levels steadily increased in both groups over time, both levels were consistently and significantly lower in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice compared to littermate controls (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>). Following an initial decrease in the first hour after lipoprotein lipase inhibition, serum APOB levels steadily rose in control mice (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). In contrast, serum APOB levels were markedly reduced at baseline in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice, and showed minimal increase after lipoprotein lipase inhibition (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p></sec><sec id="s2-4"><title>Intestinal lipid absorption and tissue lipid uptake are unaffected in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice</title><p>To assess the potential role of hepatic <italic>Surf4</italic> gene expression on dietary lipid absorption, mice were fed a <sup>3</sup>H triolein-labelled lipid load following an overnight fast. No significant differences in blood glucose, serum triglycerides, non-esterified fatty acids, or total intestinal uptake of dietary lipids were observed between control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>). Similarly, no significant differences were observed in tissue lipid uptake or fatty acid oxidation between <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice and littermate controls (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Inactivation of hepatic <italic>Surf4</italic> does not impact dietary lipid absorption, incorporation, and oxidation.</title><p>Mice were administered <sup>3</sup>H-labelled triolein by oral gavage. Blood samples were collected over 4 hr and assayed for (<bold>A</bold>) glucose, (<bold>B</bold>) triglycerides, (<bold>C</bold>) non-esterified fatty acids (NEFA), and (<bold>D</bold>) <sup>3</sup>H radioactivity. Data are presented as mean ± SEM for each time point (n=5 per genotype), n.s., not significant. (<bold>E–F</bold>) Tissues were collected at the 4 hr time point and lipids were extracted by the Folch’s method. <sup>3</sup>H radioactivity was measured in the hydrophobic phase, which represents incorporated triolein (<bold>E</bold>) and hydrophilic phase, which represents oxidized triolein (<bold>F</bold>) (n=5 per genotype). All crossbars represent the mean. The denoted p-values were obtained by two-sided Student’s t-test with Benjamini-Hochberg adjustment for multiple hypothesis testing.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>Loss of liver <italic>Surf4</italic> expression results in mild lipid accumulation but no steatohepatitis or fibrosis</title><p><italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice exhibited mildly enlarged livers (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), with a small increase in hepatic fat content and a reduction in lean mass compared to littermate controls (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). However, no differences were observed in fasting hepatic cholesterol, triglyceride, phospholipid, or nonesterified fatty acid content (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Hepatic lipid accumulation can lead to steatohepatitis and liver damage (<xref ref-type="bibr" rid="bib19">Ipsen et al., 2018</xref>). However, at 8–12 week of age, serum albumin, bilirubin, and liver function markers were indistinguishable between <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> and control mice (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and <xref ref-type="fig" rid="fig5">Figure 5D</xref>) and histologic analyses detected no evidence for steatohepatitis or fibrosis (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Finally, deep sequencing of liver mRNA identified only limited gene expression changes in response to <italic>Surf4</italic> deletion (<xref ref-type="fig" rid="fig5">Figure 5F</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Significant downregulation was observed for several genes involved in fatty acid biosynthesis processes (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). The most significantly upregulated gene in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice is <italic>Derl3</italic>, a component of the ER-associated degradation (ERAD) pathway, which could be induced by protein accumulation in the ER of <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. Genes involved in the unfolded protein response, such as <italic>Ire1</italic>, <italic>Aft6</italic>, and <italic>Perk</italic> (<xref ref-type="bibr" rid="bib17">Hetz et al., 2020</xref>), are not upgregulated in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Hepatic <italic>Surf4</italic> deletion results in mild hepatomegaly and an increase in liver lipid content, without apparent liver dysfunction or steatohepatitis.</title><p>(<bold>A</bold>) Relative liver mass in control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice presented as percentage of total body mass (n=11 per genotype). (<bold>B</bold>) Relative fat and lean mass in the livers of control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice measured by EchoMRI and presented as percentage of liver mass (n=5 per group). (<bold>C</bold>) Levels of cholesterol (Chol, mg/g tissue), triglycerides (TG, mg/g tissue), phospholipids (PL, mg/g tissue), and nonesterified fatty acid (NEFA, mEq/g tissue) in lipids extracted from the livers (n=4 per genotype). (<bold>D</bold>) Serum levels of asparate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) (n=4 per genotype). (<bold>E</bold>) Hematoxylin and eosin (H&amp;E) and picrosirius red stained liver sections from control and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (n=4 per genotype). Scale bars represent 200 µm in H&amp;E images and 300 µm in picrosirius red images. (<bold>F</bold>) Changes in mRNA transcript levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice compared to littermate controls (n=3 per genotype). Horizontal line represents the p-value above which the false discovery rate (FDR) is less than 0.01. Significantly up (blue) or down (red) regulated transcripts are labelled. (<bold>G</bold>) Significantly overrepresented Gene Ontology (GO) terms for biological processes in up and downregulated gene lists. For panels A-D: All crossbars represent the mean. p-values were obtained by two-sided Student’s t-test with Benjamini-Hochberg adjustment for multiple hypothesis testing where appropriate.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Serum (<bold>A</bold>) albumin and (<bold>B</bold>) bilirubin levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>-</sup></italic> and <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice.</title><p>Crossbars represent the mean. p-values were obtained from two-sided Student’s t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Dose-dependent reduction of plasma lipids in response to depletion of SURF4 by siRNA</title><p>To confirm the profound hypocholesterolemia with few adverse consequences observed in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice, and to further explore SURF4 inhibition as a potential therapeutic approach, we next tested depletion of hepatic SURF4 using liver-targeted siRNA in adult mice. Mice were treated with control or <italic>Surf4</italic> targeting siRNA at multiple doses between 0.5 and 4 mg/kg. Mice treated with <italic>Surf4</italic> targeting siRNA demonstrated a dose-dependent reduction of liver <italic>Surf4</italic> mRNA and protein levels (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). As expected, plasma PCSK9, cholesterol, triglycerides, APOB, and APOA1 levels were inversely correlated with siRNA dosage, with the highest siRNA dose (4 mg/kg) resulting in cholesterol levels similar to those observed in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Finally, no differences in plasma ALT and AST levels were observed between control and siRNA treated mice, suggesting that siRNA treatment and <italic>Surf4</italic> depletion does not lead to liver injury, even at the highest siRNA dose (<xref ref-type="fig" rid="fig6">Figure 6E–F</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Depletion of hepatic <italic>Surf4</italic> by siRNA recapitulates the hypolipidemia seen in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice.</title><p>(<bold>A</bold>) Normalized (Norm.) liver <italic>Surf4</italic> mRNA levels in mice treated with scrambled siRNA (control) or varying concentrations of <italic>Surf4</italic> targeting siRNA (n=5 per group). (<bold>B–D</bold>) Plasma PCSK9, cholesterol, and triglyceride levels in control and siRNA treated mice. (<bold>E–F</bold>) Plasma levels of asparate aminotransferase (AST) and alanine transaminase (ALT) in mice treated with control or increasing doses of <italic>Surf4</italic> targeting siRNA. Statistical significance was computed by one-way ANOVA test followed by Tukey’s post hoc test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Immunoblots of plasma and liver lysates collected from mice treated with control or increasing doses of <italic>Surf4</italic> targeting siRNA (<xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref>).</title><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Uncropped and unedited blots shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-82269-fig6-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82269-fig6-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We found that embryonic deletion of <italic>Surf4</italic> in hepatocytes results in profound hypocholesterolemia in mice associated with impaired hepatic lipoprotein secretion and normal dietary fat absorption. In addition, we also demonstrated that plasma PCSK9 levels are reduced in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. Hepatocyte specific <italic>Surf4</italic> deletion is well tolerated, with only modest increases in hepatic mass and lipid content, and no evidence of hepatic dysfunction or steatohepatitis. Finally, we confirm these findings by siRNA depletion of hepatic SURF4 in adult mice, which leads to reductions of plasma cholesterol, triglycerides, and PCSK9 in a dose dependent manner without apparent deleterious consequences in the liver.</p><p>We previously reported that PCSK9 is dependent on SURF4 for efficient secretion in cultured HEK293T cells (<xref ref-type="bibr" rid="bib11">Emmer et al., 2018</xref>). In contrast, Shen et al reported that depletion of SURF4 by siRNA in cultured human hepatocytes leads to increased <italic>Pcsk9</italic> gene expression resulting in increased rather than decreased PCSK9 secretion (<xref ref-type="bibr" rid="bib35">Shen et al., 2020</xref>). The same group also recently reported analysis of <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice, observing no change in plasma PCSK9 levels, in contrast to our findings in a similar genetic model. Our current findings, using three independent mouse models, are consistent with our previous in vitro data and support a physiologic role for SURF4 in facilitating the efficient transport of PCSK9 (as well as APOB) through the secretory pathway. The decrease in plasma PCSK9 in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice is similar to that observed in SEC24A-deficient mice (<xref ref-type="bibr" rid="bib7">Chen et al., 2013</xref>). Additionally, we also detected a 1.5-fold increase in LDLR level in liver lysates collected from <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice, consistent with the reduction in circulating PCSK9. The increased hepatocyte LDLR levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice are not accompanied by upregulation of <italic>Ldlr</italic> mRNA as measured by RNA-seq analysis, consistent with the increase in LDLR abundance being mediated by PCSK9 activity rather than an increase in gene expression. Furthermore, a recent report by Gomez-Navarro et al independently demonstrated that PCSK9 relies on both SEC24A and SURF4 for secretion and that chemical disruption of SEC24A-SURF4 interaction is sufficient to reduce PCSK9 secretion (<xref ref-type="bibr" rid="bib16">Gomez-Navarro et al., 2022</xref>). Taken together, these data are consistent with the proposed function of SURF4 as a cargo receptor linking PCSK9 in the ER lumen to the SEC24A component of the COPII coat on the cytoplasmic face of the ER (<xref ref-type="bibr" rid="bib11">Emmer et al., 2018</xref>). The basis for the discrepancy between our findings and those of B. Wang and colleagues (<xref ref-type="bibr" rid="bib38">Wang et al., 2021a</xref>) is unclear but may be related to differences in mouse genetic or husbandry (<xref ref-type="bibr" rid="bib37">Tang et al., 2017</xref>), or to technical differences in PCSK9 quantification.</p><p>The profound hypocholesterolemia we observed in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice is in agreement with two other studies in which hepatic <italic>Surf4</italic> was acutely inactivated using an AAV/Cas9 mouse system (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>) or a similar <italic>Surf4<sup>fl/fl</sup></italic> and <italic>Alb-Cre</italic> model (<xref ref-type="bibr" rid="bib38">Wang et al., 2021a</xref>). We also confirmed this observation in a third model using siRNA-mediated knockdown of <italic>Surf4</italic> transcripts in mouse livers. The decrease in circulating cholesterol is likely due to impaired secretion of APOB containing lipoprotein particles from the liver, and is consistent with multiple previous reports suggesting that APOB is a cargo for SURF4 (<xref ref-type="bibr" rid="bib12">Emmer et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Saegusa et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Wang et al., 2021a</xref>; <xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>). Despite remarkably low plasma cholesterol levels, <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice exhibit normal growth and fertility compared to littermate controls. Plasma cholesterol is an important precursor for steroid hormone synthesis. However, given that both male and female <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice are fertile, it is unlikely that sex hormone synthesis is significantly perturbed in these mice. Consistent with this conclusion, Chang et al recently reported that even though lipid droplets and cholesterol are depleted in the adrenal glands of <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice, circulating adrenal steroid hormone levels are unchanged under resting and stressed conditions (<xref ref-type="bibr" rid="bib5">Chang et al., 2021</xref>).</p><p>Impaired protein secretion could lead to accumulation of proteins in the ER lumen, potentially triggering activation of unfolded protein response pathways and induction of ERAD. Indeed, livers from <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice exhibited upregulation of mRNA for <italic>Derl3</italic>, an ER transmembrane protein that is a functional component of the ERAD complex (<xref ref-type="bibr" rid="bib29">Oda et al., 2006</xref>). While <italic>Derl3</italic> is thought to be a target of the IRE1-XBP1 pathway, we did not detect upregulation of <italic>Ire1</italic> or <italic>Xbp1</italic>, or other ERAD components at the mRNA levels in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. Instead upregulation of <italic>Derl3</italic> could be an adaptive response to the protein accumulation in the ER leading to the rapid degradation of these proteins. This can also explain the lack of liver PCSK9 accumulation and a mild increase in liver APOB levels (relative to a significant reduction of plasma levels) in <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice.</p><p>Recently, Musunuru et al reported that in vivo CRISPR-mediated base editing of hepatic <italic>PCSK9</italic> leads to an ~60% reduction in plasma cholesterol in cynomolgus monkeys without overt hepatotoxicity (<xref ref-type="bibr" rid="bib28">Musunuru et al., 2021</xref>). Our data suggest that hepatic <italic>Surf4</italic> could be similarly targeted, potentially achieving an even more profound reduction in plasma cholesterol without deleterious consequences. Indeed, it has been shown that inactivation of hepatic <italic>Surf4</italic> is protective against diet-induced atherosclerosis in mice with PCSK9 overexpression (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>), LDLR deficiency (<xref ref-type="bibr" rid="bib38">Wang et al., 2021a</xref>), and APOE deficiency (<xref ref-type="bibr" rid="bib36">Shen et al., 2022</xref>). Furthermore, polymorphism and mild reduction of <italic>SURF4</italic> expression strongly associate with lower plasma lipid levels and reduced risks of cardiovascular disease in human populations (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>). Here, we further demonstrate that even more modest reductions in SURF4 induced by siRNA targeting are likely to confer significant lipid-lowering, though such benefits must be weighed against potential toxicity from disrupting the secretion of other SURF4-dependent cargoes.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Surf4<sup>fl</sup> mice (C57BL/6 J)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Albumin-Cre mice (C57BL/6 J)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Adams et al., 2014</xref></td><td align="left" valign="bottom">JAX 003574</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup> mice (C57BL/6 J)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">SpCas9 mice</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Platt et al., 2014</xref></td><td align="left" valign="bottom">JAX 026556</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6 J mice</td><td align="left" valign="bottom">Jackson lab</td><td align="left" valign="bottom">JAX 0006640</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (include species here)</td><td align="left" valign="bottom">AAV-Cre-sgRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-APOB - rabbit polyclonal</td><td align="left" valign="bottom">Fitzgerald Industries Internationa</td><td align="char" char="." valign="bottom">70 R-15771</td><td align="left" valign="bottom">WB(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PCSK9 – rabbit polyclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab31762</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LDLR – rabbit monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab52818</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HSP90 – rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">4877</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SURF4 – rabbit polyclonal</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-APOA1 – rabbit polyclonal</td><td align="left" valign="bottom">Fitzgerald Industries Internationa</td><td align="char" char="." valign="bottom">70 R-15769</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Albumin – mouse monoclonal</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="." valign="bottom">66051</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tubulin – rabbit polyclonal</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="ndash" valign="bottom">10094–1-AP</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH – rabbit monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab181602</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primers</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequences are listed in Supplement File 1</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CRISPR-gRNA</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequences are listed in Supplement File 2</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SURF4-targeting siRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequences are listed in Supplement File 3</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Cholesterol assay kit</td><td align="left" valign="bottom">SB-1010–225</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PCSK9 ELSIA</td><td align="left" valign="bottom">MPC900</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">APOB ELISA</td><td align="left" valign="bottom">ab230932</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Triglycerides assay</td><td align="left" valign="bottom">10010303</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Plus Mini Kit</td><td align="left" valign="bottom">74134</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Power SYBR Green PCR Master Mix</td><td align="left" valign="bottom">4367659</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal care and use</title><p>All animal care and use complied with the Principles of Laboratory and Animal Care established by the National Society for Medical Research. Mice were housed in a controlled lighting (12 hr light/dark cycle) and temperature (22 °C) environment and had free access to food (5L0D, LabDiet, St. Louis, MO) and water. All animal protocols in this study have been approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan (protocol number PRO00009304) and the IACUC of Peking University. Both male and female mice were used in this study unless otherwise specified.</p></sec><sec id="s4-2"><title>Generation of conditional <italic>Surf4</italic> knockout mice</title><p>The generation of mice carrying a conditional <italic>Surf4</italic> allele in which exon 2 of the gene is flanked by 2 loxP sites (<italic>Surf4<sup>fl</sup></italic>) has been previously described (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>). <italic>Surf4<sup>fl/+</sup></italic> mice were crossed with mice carrying an <italic>Alb-Cre</italic> transgene (<xref ref-type="bibr" rid="bib1">Adams et al., 2014</xref>) to obtain <italic>Surf4<sup>fl/+</sup> Alb-Cre<sup>+</sup></italic> mice. These mice were then crossed to <italic>Surf4<sup>fl/fl</sup></italic> mice to generate <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice. The <italic>Surf4<sup>fl</sup></italic> and <italic>Alb-Cre</italic> alleles were maintained on the C57BL/6 J background by continuous backcrosses to C57BL/6 J mice (0006640, Jackson Laboratory, Bar Harbor ME).</p></sec><sec id="s4-3"><title>Genotyping assays</title><p>Tail clips were obtained from 2 weeks old mice for genomic DNA isolation and genotyping. PCR was performed using Go-Taq Green Master Mix (Promega, Madison, WI) and resulting products were resolved by 3% agarose gel electrophoresis. All primers used for genotyping are listed in (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Those used for genotyping the <italic>Surf4</italic> locus are also depicted in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. For the <italic>Alb-Cre</italic> transgene, parental mice were genotyped using promoter-specific <italic>Cre</italic> primers and offspring were genotyped with primers that detect the <italic>Cre</italic> transgene (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p></sec><sec id="s4-4"><title>Blood and tissue collection</title><p>Mice were fasted overnight for up to 16 hr prior to sample collection. For non-terminal experiments, blood was collected from the superficial temporal vein using a 4 mm sterile lancet. For terminal experiments, mice were first euthanized by isoflurane inhalation and blood was drawn from the inferior vena cava using a 23 G needle and a 1 ml syringe. Blood was collected into a serum separator tube (365967, BD, Franklin Lakes NJ), allowed to clot at room temperature for at least 10 min, and centrifuged at 15,000 g for 10 min to separate serum. Sera were aliquoted and stored at –80 °C. Liver tissue were collected as previously described (<xref ref-type="bibr" rid="bib12">Emmer et al., 2020</xref>).</p></sec><sec id="s4-5"><title>Analysis for sera from <italic>Surf4<sup>fl/fl</sup> Alb-Cre<sup>+</sup></italic> mice</title><p>Sera were analyzed by a colorimetric assay for total cholesterol (SB-1010–225, Fisher Scientific, Hampton NH) and by ELISAs for PCSK9 (MPC900, R&amp;D Systems, Minneapolis MN) and APOB (ab230932, abcam, Cambridge UK). Serum lipoprotein fractionation assays were performed at the University of Cincinnati Mouse Metabolic Phenotyping Center. Sera were pooled from 5 mice for each genotype and fractionated by fast liquid protein chromatography (FPLC) into 50 fractions. Cholesterol (NC9343696, Fisher, Hampton NH) and triglyceride (TR213, Randox Laboratories, Crumlin UK) content in each fraction were determined using a microliter plate enzyme-based assay. Liver function tests were performed at the University of Michigan In-Vivo Animal Core (IVAC) with sera collected from individual mice using a Liasys analyzer (AMS Alliance).</p></sec><sec id="s4-6"><title>Hepatic lipoprotein secretion assay</title><p>Hepatic triglyceride secretion assays were performed at the University of Michigan Mouse Metabolic Phenotyping Center as previously described (<xref ref-type="bibr" rid="bib25">Millar et al., 2005</xref>). Blood levels of glucose were measured using a glucometer (Acucheck, Roche, Basel Switzerland) and plasma levels of cholesterol (SB-1010–225, Fisher Scientific, Hampton NH) and triglycerides (10010303, Cayman Chemical, Ann Arbor MI) were determined using colorimetric assay kits. Plasma APOB levels were determined by ELISA (ab230932, abcam, Cambridge UK).</p></sec><sec id="s4-7"><title>Oral fat tolerance test and lipid flux assay</title><p>Oral fat tolerance test and lipid flux assay were performed at the University of Michigan Mouse Metabolic Phenotyping Center. Mice were fasted overnight and <sup>3</sup>H triolein-labeled olive oil (0.026 µCi/µl) was given via oral gavage at 5 µl/g of body mass. Blood samples were collected at time 0, 30, 60, 120, and 240 min after the gavage via tail vein bleeding. Plasma levels of triglyceride (10010303, Cayman Chemical, Ann Arbor MI) and non-esterified fatty acid (NEFA-HR (H2), Wako Pure Chemical Industries, Ltd, Richmond VA) were determined using the colorimetric assays. Plasma radioactivity, reported as <sup>3</sup>H disintegration per minute (dpm), were determined from 2 µl of serum at each time point.</p><p>Tissues samples (liver, heart, gastrocnemius muscle, and perigonadal fat) were collected at the 240 min time point, flash frozen in liquid nitrogen and stored at –80 °C. For the liver, tissue composition was measured using an NMR-based analyzer (EchoMRI) immediately upon harvest and prior to freezing. <sup>3</sup>H-triolein flux was estimated as previously described (<xref ref-type="bibr" rid="bib21">Kusminski et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Ye et al., 2014</xref>).</p></sec><sec id="s4-8"><title>Liver lipid extraction and quantification</title><p>Liver lipid extraction and quantification were performed at the University of Cincinnati Mouse Metabolic Phenotyping Center. Lipids were extracted using the Folch’s extraction method as previously described (<xref ref-type="bibr" rid="bib13">Folch et al., 1957</xref>). Levels of cholesterol, triglycerides, free fatty acids, and phospholipids in each sample were quantified using specific colorimetric assays.</p></sec><sec id="s4-9"><title>Immunoblotting</title><p>Lysates were prepared from snap frozen liver tissues and resolved on a 4–20% Tris-glycine gel as previously described (<xref ref-type="bibr" rid="bib12">Emmer et al., 2020</xref>). Immunoblots were probed with antibodies against APOB (70 R-15771, 1:1000, Fitzgerald Industries International, Acton MA), PCSK9 (ab31762, 1:1000, abcam, Cambridge UK), LDLR (ab52818, 1:1000, abcam, Cambridge UK), HSP90 (4877, 1:1000, Cell Signaling Technology, Danvers MA), SURF4 (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>), APOA1 (70 R-15769, 1:1000, Fitzgerald Industries International, Acton MA), Albumin (66051, 1:1000, Proteintech, Rosemont, IL), Tubulin (10094–1-AP, 1:1000, Proteintech, Rosemont, IL), and GAPDH (ab181602, 1:5000, abcam, Cambridge UK). For endoglycosidase H assays, 30 µg of lysate was analyzed as previously described using the above antibodies (<xref ref-type="bibr" rid="bib11">Emmer et al., 2018</xref>).</p></sec><sec id="s4-10"><title>Histology</title><p>Tissue processing, embedding, sectioning, hematoxylin and eosin (H&amp;E), and picrosirius red staining were performed at the University of Michigan In-Vivo Animal Core (IVAC). Slides were reviewed by an investigator blinded to the genotype.</p></sec><sec id="s4-11"><title>Analysis of liver mRNA</title><p>Liver RNA was isolated from tissue using an RNeasy Plus Mini Kit according to the manufacturer’s instructions (74134, Qiagen, Hilden Germany) and reverse transcription was performed using oligo(dT)<sub>12-18</sub> primers (18418012, Invitrogen, Waltham MA). Quantitative PCR reactions were performed using Power SYBR Green PCR Master Mix (4367659, Invitrogen, Waltham MA) and primers listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Total <italic>Surf4</italic> mRNA abundance was calculated using data from primers that bind to exon 5 and 6 on the <italic>Surf4</italic> transcript. Abundance of <italic>Surf4</italic> mRNA that contains exon 2 was obtained using primers specific to exon 2 and exon 3 of the transcript. Normalized transcript abundance was calculated by the 2<sup>-ΔΔCt</sup> method using <italic>Gapdh</italic> and <italic>Rpl37</italic> as housekeeping controls.</p><p>Library preparation and next generation sequencing was performed at the University of Michigan Advanced Genomics Core. Demultiplexed fastq files were aligned against the mouse reference genome (GRCm38.92) using STAR (<xref ref-type="bibr" rid="bib10">Dobin et al., 2013</xref>) and quantified with RSEM (<xref ref-type="bibr" rid="bib22">Li and Dewey, 2011</xref>). Differential expression analysis was performed by DESeq2 (<xref ref-type="bibr" rid="bib24">Love et al., 2014</xref>; <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Sequencing coverage for the <italic>Surf4</italic> transcript was analyzed using the ggsashimi package (<xref ref-type="bibr" rid="bib15">Garrido-Martín et al., 2018</xref>). Raw and processed sequencing data have been deposited to GEO (accession number GSE214393).</p></sec><sec id="s4-12"><title>Acute inactivation of hepatic <italic>Surf4</italic> in adult mice</title><p>Hepatic <italic>Surf4</italic> was selectively inactivated in adult mice by injection of adeno-associated virus (AAV) delivering a hepatocyte-specific <italic>Cre</italic> and a guide RNA targeting <italic>Surf4</italic> or <italic>LacZ</italic> (control) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) into a Cre-dependent spCas9 knockin mice (<xref ref-type="bibr" rid="bib31">Platt et al., 2014</xref>) as previously described (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>). Blood samples were collected as previously described (<xref ref-type="bibr" rid="bib39">Wang et al., 2021b</xref>) and plasma PCSK9 concentrations were measured by the commercial kit (CY-8078 of MBL) according to the manufacturer’s protocol.</p><p>To deplete <italic>Surf4</italic> mRNA, N-acetylgalactosamine (GalNAc) conjugated siRNA oligos are synthesized to ensure liver targeting. SiRNA targeting murine <italic>Surf4</italic> or GalNAc conjugated siRNA with scrambled sequence (siCTL) were injected into 6 weeks old male mice subcutaneously with concentrations indicated in the figures. Seven days after injection, blood samples were collected by tail vein, and then centrifuged at 6000 rpm, 4℃ for 10 min to harvest plasma. The plasma PCSK9 concentrations were measured by the commercial kit (CY-8078 of MBL) according to the manufacturer’s protocol. SiRNA sequences are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Software, Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal care and use complied with the Principles of Laboratory and Animal Care established by the National Society for Medical Research. All animal protocols in this study have been approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan (protocol number PRO00009304) and the IACUC of Peking University.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-82269-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primer sequences used in this study.</title></caption><media xlink:href="elife-82269-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Guide RNA (gRNA) sequence used for AAV-CRISPR mediated hepatic <italic>Surf4</italic> inactivation.</title></caption><media xlink:href="elife-82269-supp2-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>siRNA sequences used to target hepatic <italic>Surf4</italic> in this study.</title></caption><media xlink:href="elife-82269-supp3-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>DESeq2 output for differential gene expression analysis of RNA-seq data.</title></caption><media xlink:href="elife-82269-supp4-v2.csv" mimetype="application" mime-subtype="octet-stream"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in GEO (accession number GSE214393). All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for figure 1, figure 2, figure 3, and figure 6-figure supplement 1.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>VT</given-names></name><name><surname>McCormick</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Siemieniak</surname><given-names>D</given-names></name><name><surname>Khoriaty</surname><given-names>R</given-names></name><name><surname>Emmer</surname><given-names>BT</given-names></name><name><surname>Chen</surname><given-names>XW</given-names></name><name><surname>Ginsburg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Hepatic inactivation of murine Surf4 results in marked reduction in plasma cholesterol</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214393">GSE214393</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by NIH grants R35HL135793 (DG), R01HL148333 (RK), R01HL157062 (RK), and K08HL148552 (BTE); the National Key R&amp;D Program grant 2018YFA0506900 (XWC); the National Science Foundation of China grants 91957119, 91954001, 31571213, and 31521062 (XWC); the American Heart Association Predoctoral Fellowship 20PRE35210706 (VTT); the University of Michigan Rackham Predoctoral Fellowship (VTT). DG is a Howard Hughes Medical Institute Investigator. Funding sources were not involved in study design, data collection and interpretation, or the decision to submit the work for publication</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>EJ</given-names></name><name><surname>Chen</surname><given-names>XW</given-names></name><name><surname>O’Shea</surname><given-names>KS</given-names></name><name><surname>Ginsburg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mammalian COPII coat component SEC24C is required for embryonic development in mice</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>20858</fpage><lpage>20870</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.566687</pub-id><pub-id pub-id-type="pmid">24876386</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belden</surname><given-names>WJ</given-names></name><name><surname>Barlowe</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Role of erv29p in collecting soluble secretory proteins into ER-derived transport vesicles</article-title><source>Science</source><volume>294</volume><fpage>1528</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1126/science.1065224</pub-id><pub-id pub-id-type="pmid">11711675</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjannet</surname><given-names>S</given-names></name><name><surname>Rhainds</surname><given-names>D</given-names></name><name><surname>Essalmani</surname><given-names>R</given-names></name><name><surname>Mayne</surname><given-names>J</given-names></name><name><surname>Wickham</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Asselin</surname><given-names>MC</given-names></name><name><surname>Hamelin</surname><given-names>J</given-names></name><name><surname>Varret</surname><given-names>M</given-names></name><name><surname>Allard</surname><given-names>D</given-names></name><name><surname>Trillard</surname><given-names>M</given-names></name><name><surname>Abifadel</surname><given-names>M</given-names></name><name><surname>Tebon</surname><given-names>A</given-names></name><name><surname>Attie</surname><given-names>AD</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Boileau</surname><given-names>C</given-names></name><name><surname>Brissette</surname><given-names>L</given-names></name><name><surname>Chrétien</surname><given-names>M</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>48865</fpage><lpage>48875</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409699200</pub-id><pub-id pub-id-type="pmid">15358785</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifacino</surname><given-names>JS</given-names></name><name><surname>Glick</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The mechanisms of vesicle budding and fusion</article-title><source>Cell</source><volume>116</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)01079-1</pub-id><pub-id pub-id-type="pmid">14744428</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>HM</given-names></name><name><surname>Zhang</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Loss of hepatic surf4 depletes lipid droplets in the adrenal cortex but does not impair adrenal hormone production</article-title><source>Frontiers in Cardiovascular Medicine</source><volume>8</volume><elocation-id>764024</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2021.764024</pub-id><pub-id pub-id-type="pmid">34859075</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name><name><surname>Amarenco</surname><given-names>P</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Borén</surname><given-names>J</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name><name><surname>Descamps</surname><given-names>OS</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name><name><surname>Kuivenhoven</surname><given-names>JA</given-names></name><name><surname>Lesnik</surname><given-names>P</given-names></name><name><surname>Masana</surname><given-names>L</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Tokgözoglu</surname><given-names>L</given-names></name><name><surname>Tybjærg-Hansen</surname><given-names>A</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><collab>European Atherosclerosis Society Consensus Panel</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management</article-title><source>European Heart Journal</source><volume>32</volume><fpage>1345</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr112</pub-id><pub-id pub-id-type="pmid">21531743</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XW</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bajaj</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Meng</surname><given-names>ZX</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>HH</given-names></name><name><surname>Adams</surname><given-names>E</given-names></name><name><surname>Baines</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Sartor</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>SG</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name><name><surname>Ginsburg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion</article-title><source>eLife</source><volume>2</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00444</pub-id><pub-id pub-id-type="pmid">23580231</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Pertsemlidis</surname><given-names>A</given-names></name><name><surname>Kotowski</surname><given-names>IK</given-names></name><name><surname>Graham</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>CK</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Low LDL cholesterol in individuals of african descent resulting from frequent nonsense mutations in PCSK9</article-title><source>Nature Genetics</source><volume>37</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/ng1509</pub-id><pub-id pub-id-type="pmid">15654334</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetics. Simple genetics for a complex disease</article-title><source>Science</source><volume>340</volume><fpage>689</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1126/science.1239101</pub-id><pub-id pub-id-type="pmid">23661745</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Star: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmer</surname><given-names>BT</given-names></name><name><surname>Hesketh</surname><given-names>GG</given-names></name><name><surname>Kotnik</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>VT</given-names></name><name><surname>Lascuna</surname><given-names>PJ</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Chen</surname><given-names>XW</given-names></name><name><surname>Ginsburg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9</article-title><source>eLife</source><volume>7</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.38839</pub-id><pub-id pub-id-type="pmid">30251625</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmer</surname><given-names>BT</given-names></name><name><surname>Lascuna</surname><given-names>PJ</given-names></name><name><surname>Tang</surname><given-names>VT</given-names></name><name><surname>Kotnik</surname><given-names>EN</given-names></name><name><surname>Saunders</surname><given-names>TL</given-names></name><name><surname>Khoriaty</surname><given-names>R</given-names></name><name><surname>Ginsburg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Murine surf4 is essential for early embryonic development</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0227450</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0227450</pub-id><pub-id pub-id-type="pmid">31978056</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folch</surname><given-names>J</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>Sloane</surname><given-names>GH</given-names></name></person-group><year iso-8601-date="1957">1957</year><article-title>A simple method for the isolation and purification of total lipides from animal tissues</article-title><source>The Journal of Biological Chemistry</source><volume>226</volume><fpage>497</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)64849-5</pub-id><pub-id pub-id-type="pmid">13428781</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeze</surname><given-names>HH</given-names></name><name><surname>Kranz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Endoglycosidase and glycoamidase release of n-linked glycans</article-title><source>Current Protocols in Protein Science</source><volume>Chapter 12</volume><elocation-id>Unit12</elocation-id><pub-id pub-id-type="doi">10.1002/0471140864.ps1204s62</pub-id><pub-id pub-id-type="pmid">21104982</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido-Martín</surname><given-names>D</given-names></name><name><surname>Palumbo</surname><given-names>E</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Breschi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ggsashimi: sashimi plot revised for browser- and annotation-independent splicing visualization</article-title><source>PLOS Computational Biology</source><volume>14</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006360</pub-id><pub-id pub-id-type="pmid">30118475</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Navarro</surname><given-names>N</given-names></name><name><surname>Maldutyte</surname><given-names>J</given-names></name><name><surname>Poljak</surname><given-names>K</given-names></name><name><surname>Peak-Chew</surname><given-names>SY</given-names></name><name><surname>Orme</surname><given-names>J</given-names></name><name><surname>Bisnett</surname><given-names>BJ</given-names></name><name><surname>Lamb</surname><given-names>CH</given-names></name><name><surname>Boyce</surname><given-names>M</given-names></name><name><surname>Gianni</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Selective inhibition of protein secretion by abrogating receptor-coat interactions during ER export</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2202080119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2202080119</pub-id><pub-id pub-id-type="pmid">35901214</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Kaufman</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms, regulation and functions of the unfolded protein response</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>21</volume><fpage>421</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0250-z</pub-id><pub-id pub-id-type="pmid">32457508</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>AJ</given-names></name><name><surname>Marais</surname><given-names>AD</given-names></name><name><surname>Tanyanyiwa</surname><given-names>DM</given-names></name><name><surname>Burnett</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The C679X mutation in PCSK9 is present and lowers blood cholesterol in a southern african population</article-title><source>Atherosclerosis</source><volume>193</volume><fpage>445</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.08.039</pub-id><pub-id pub-id-type="pmid">16989838</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ipsen</surname><given-names>DH</given-names></name><name><surname>Lykkesfeldt</surname><given-names>J</given-names></name><name><surname>Tveden-Nyborg</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease</article-title><source>Cellular and Molecular Life Sciences</source><volume>75</volume><fpage>3313</fpage><lpage>3327</lpage><pub-id pub-id-type="doi">10.1007/s00018-018-2860-6</pub-id><pub-id pub-id-type="pmid">29936596</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolovou</surname><given-names>G</given-names></name><name><surname>Vasiliadis</surname><given-names>I</given-names></name><name><surname>Gontoras</surname><given-names>N</given-names></name><name><surname>Kolovou</surname><given-names>V</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance</article-title><source>Cardiovascular Therapeutics</source><volume>33</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/1755-5922.12105</pub-id><pub-id pub-id-type="pmid">25604780</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusminski</surname><given-names>CM</given-names></name><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Spurgin</surname><given-names>SB</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Askew</surname><given-names>GR</given-names></name><name><surname>Simcox</surname><given-names>JA</given-names></name><name><surname>McClain</surname><given-names>DA</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity</article-title><source>Nature Medicine</source><volume>18</volume><fpage>1539</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1038/nm.2899</pub-id><pub-id pub-id-type="pmid">22961109</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Dewey</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>King</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>V</given-names></name><name><surname>Myers</surname><given-names>G</given-names></name><name><surname>Balbin-Cuesta</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>A</given-names></name><name><surname>McGee</surname><given-names>B</given-names></name><name><surname>Desch</surname><given-names>K</given-names></name><name><surname>Ozel</surname><given-names>AB</given-names></name><name><surname>Siemieniak</surname><given-names>D</given-names></name><name><surname>Reddy</surname><given-names>P</given-names></name><name><surname>Emmer</surname><given-names>B</given-names></name><name><surname>Khoriaty</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The endoplasmic reticulum cargo receptor SURF4 facilitates efficient erythropoietin secretion</article-title><source>Molecular and Cellular Biology</source><volume>40</volume><elocation-id>e00180-20</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00180-20</pub-id><pub-id pub-id-type="pmid">32989016</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname><given-names>JS</given-names></name><name><surname>Cromley</surname><given-names>DA</given-names></name><name><surname>McCoy</surname><given-names>MG</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Billheimer</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with triton WR-1339</article-title><source>Journal of Lipid Research</source><volume>46</volume><fpage>2023</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1194/jlr.D500019-JLR200</pub-id><pub-id pub-id-type="pmid">15995182</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Antonny</surname><given-names>B</given-names></name><name><surname>Hamamoto</surname><given-names>S</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cargo selection into COPII vesicles is driven by the sec24p subunit</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>6105</fpage><lpage>6113</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdf605</pub-id><pub-id pub-id-type="pmid">12426382</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitrovic</surname><given-names>S</given-names></name><name><surname>Ben-Tekaya</surname><given-names>H</given-names></name><name><surname>Koegler</surname><given-names>E</given-names></name><name><surname>Gruenberg</surname><given-names>J</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The cargo receptors surf4, endoplasmic reticulum-golgi intermediate compartment (ERGIC) -53, and p25 are required to maintain the architecture of ERGIC and golgi</article-title><source>Molecular Biology of the Cell</source><volume>19</volume><fpage>1976</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1091/mbc.E07-10-0989</pub-id><pub-id pub-id-type="pmid">18287528</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musunuru</surname><given-names>K</given-names></name><name><surname>Chadwick</surname><given-names>AC</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Garcia</surname><given-names>SP</given-names></name><name><surname>DeNizio</surname><given-names>JE</given-names></name><name><surname>Reiss</surname><given-names>CW</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Dutta</surname><given-names>C</given-names></name><name><surname>Clendaniel</surname><given-names>V</given-names></name><name><surname>Amaonye</surname><given-names>M</given-names></name><name><surname>Beach</surname><given-names>A</given-names></name><name><surname>Berth</surname><given-names>K</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Braun</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>HM</given-names></name><name><surname>Colace</surname><given-names>TV</given-names></name><name><surname>Ganey</surname><given-names>JD</given-names></name><name><surname>Gangopadhyay</surname><given-names>SA</given-names></name><name><surname>Garrity</surname><given-names>R</given-names></name><name><surname>Kasiewicz</surname><given-names>LN</given-names></name><name><surname>Lavoie</surname><given-names>J</given-names></name><name><surname>Madsen</surname><given-names>JA</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Mazzola</surname><given-names>AM</given-names></name><name><surname>Nasrullah</surname><given-names>YS</given-names></name><name><surname>Nneji</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Sanjeev</surname><given-names>A</given-names></name><name><surname>Shay</surname><given-names>M</given-names></name><name><surname>Stahley</surname><given-names>MR</given-names></name><name><surname>Fan</surname><given-names>SHY</given-names></name><name><surname>Tam</surname><given-names>YK</given-names></name><name><surname>Gaudelli</surname><given-names>NM</given-names></name><name><surname>Ciaramella</surname><given-names>G</given-names></name><name><surname>Stolz</surname><given-names>LE</given-names></name><name><surname>Malyala</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>CJ</given-names></name><name><surname>Rajeev</surname><given-names>KG</given-names></name><name><surname>Rohde</surname><given-names>E</given-names></name><name><surname>Bellinger</surname><given-names>AM</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates</article-title><source>Nature</source><volume>593</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03534-y</pub-id><pub-id pub-id-type="pmid">34012082</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Kaufman</surname><given-names>RJ</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Derlin-2 and derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation</article-title><source>The Journal of Cell Biology</source><volume>172</volume><fpage>383</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1083/jcb.200507057</pub-id><pub-id pub-id-type="pmid">16449189</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palade</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Intracellular aspects of the process of protein synthesis</article-title><source>Science</source><volume>189</volume><fpage>347</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1126/science.1096303</pub-id><pub-id pub-id-type="pmid">1096303</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yim</surname><given-names>MJ</given-names></name><name><surname>Swiech</surname><given-names>L</given-names></name><name><surname>Kempton</surname><given-names>HR</given-names></name><name><surname>Dahlman</surname><given-names>JE</given-names></name><name><surname>Parnas</surname><given-names>O</given-names></name><name><surname>Eisenhaure</surname><given-names>TM</given-names></name><name><surname>Jovanovic</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Heidenreich</surname><given-names>M</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-cas9 knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popp</surname><given-names>MWL</given-names></name><name><surname>Maquat</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Organizing principles of mammalian nonsense-mediated mrna decay</article-title><source>Annual Review of Genetics</source><volume>47</volume><fpage>139</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-111212-133424</pub-id><pub-id pub-id-type="pmid">24274751</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>S</given-names></name><name><surname>Curtis</surname><given-names>DE</given-names></name><name><surname>Garuti</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>NN</given-names></name><name><surname>Bashmakov</surname><given-names>Y</given-names></name><name><surname>Ho</surname><given-names>YK</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Moon</surname><given-names>YA</given-names></name><name><surname>Horton</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9</article-title><source>PNAS</source><volume>102</volume><fpage>5374</fpage><lpage>5379</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501652102</pub-id><pub-id pub-id-type="pmid">15805190</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saegusa</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Morooka</surname><given-names>N</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SFT-4/surf4 control ER export of soluble cargo proteins and participate in ER exit site organization</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>2073</fpage><lpage>2085</lpage><pub-id pub-id-type="doi">10.1083/jcb.201708115</pub-id><pub-id pub-id-type="pmid">29643117</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>HM</given-names></name><name><surname>Alabi</surname><given-names>A</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Surf4 regulates expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) but is not required for PCSK9 secretion in cultured human hepatocytes</article-title><source>Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids</source><volume>1865</volume><elocation-id>158555</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbalip.2019.158555</pub-id><pub-id pub-id-type="pmid">31676436</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>HM</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The role of hepatic surf4 in lipoprotein metabolism and the development of atherosclerosis in apoe-/- mice</article-title><source>Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids</source><volume>1867</volume><elocation-id>159196</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbalip.2022.159196</pub-id><pub-id pub-id-type="pmid">35803528</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>AT</given-names></name><name><surname>Choi</surname><given-names>JP</given-names></name><name><surname>Kotzin</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>CC</given-names></name><name><surname>Hobson</surname><given-names>N</given-names></name><name><surname>Girard</surname><given-names>R</given-names></name><name><surname>Zeineddine</surname><given-names>HA</given-names></name><name><surname>Lightle</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>T</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Shenkar</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Mericko</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Tanes</surname><given-names>C</given-names></name><name><surname>Kobuley</surname><given-names>D</given-names></name><name><surname>Võsa</surname><given-names>U</given-names></name><name><surname>Whitehead</surname><given-names>KJ</given-names></name><name><surname>Li</surname><given-names>DY</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><name><surname>Hart</surname><given-names>B</given-names></name><name><surname>Schwaninger</surname><given-names>M</given-names></name><name><surname>Henao-Mejia</surname><given-names>J</given-names></name><name><surname>Morrison</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Awad</surname><given-names>IA</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Kahn</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial TLR4 and the microbiome drive cerebral cavernous malformations</article-title><source>Nature</source><volume>545</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/nature22075</pub-id><pub-id pub-id-type="pmid">28489816</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Alabi</surname><given-names>A</given-names></name><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein surf4</article-title><source>Journal of Lipid Research</source><volume>62</volume><elocation-id>100091</elocation-id><pub-id pub-id-type="doi">10.1016/j.jlr.2021.100091</pub-id><pub-id pub-id-type="pmid">34118252</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Nie</surname><given-names>C</given-names></name><name><surname>Pu</surname><given-names>L</given-names></name><name><surname>Zajac</surname><given-names>GJM</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Emmer</surname><given-names>BT</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Willer</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>XW</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Receptor-mediated ER export of lipoproteins controls lipid homeostasis in mice and humans</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>350</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.10.020</pub-id><pub-id pub-id-type="pmid">33186557</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendeler</surname><given-names>MW</given-names></name><name><surname>Paccaud</surname><given-names>JP</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name><name><surname>Appenzeller</surname><given-names>C</given-names></name><name><surname>Andersson</surname><given-names>H</given-names></name><name><surname>Kappeler</surname><given-names>F</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name><name><surname>Appenzeller‐Herzog</surname><given-names>C</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name><name><surname>Barlowe</surname><given-names>C</given-names></name><name><surname>Barlowe</surname><given-names>C</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Yeung</surname><given-names>T</given-names></name><name><surname>Hosobuchi</surname><given-names>M</given-names></name><name><surname>Hamamoto</surname><given-names>S</given-names></name><name><surname>Salama</surname><given-names>N</given-names></name><name><surname>Rexach</surname><given-names>MF</given-names></name><name><surname>Ravazzola</surname><given-names>M</given-names></name><name><surname>Amherdt</surname><given-names>M</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name><name><surname>Kappeler</surname><given-names>F</given-names></name><name><surname>Klopfenstein</surname><given-names>DR</given-names></name><name><surname>Foguet</surname><given-names>M</given-names></name><name><surname>Paccaud</surname><given-names>JP</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hamamoto</surname><given-names>S</given-names></name><name><surname>Ravazzola</surname><given-names>M</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name><name><surname>Kurihara</surname><given-names>T</given-names></name><name><surname>Hamamoto</surname><given-names>S</given-names></name><name><surname>Gimeno</surname><given-names>RE</given-names></name><name><surname>Kaiser</surname><given-names>CA</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name><name><surname>Yoshihisa</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Miller</surname><given-names>EA</given-names></name><name><surname>Goldberg</surname><given-names>J</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>EA</given-names></name><name><surname>Beilharz</surname><given-names>TH</given-names></name><name><surname>Malkus</surname><given-names>PN</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Hamamoto</surname><given-names>S</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name><name><surname>Mossessova</surname><given-names>E</given-names></name><name><surname>Bickford</surname><given-names>LC</given-names></name><name><surname>Goldberg</surname><given-names>J</given-names></name><name><surname>Nichols</surname><given-names>WC</given-names></name><name><surname>Nishimura</surname><given-names>N</given-names></name><name><surname>Balch</surname><given-names>WE</given-names></name><name><surname>Nufer</surname><given-names>O</given-names></name><name><surname>Guldbrandsen</surname><given-names>S</given-names></name><name><surname>Degen</surname><given-names>M</given-names></name><name><surname>Kappeler</surname><given-names>F</given-names></name><name><surname>Paccaud</surname><given-names>JP</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name><name><surname>Nufer</surname><given-names>O</given-names></name><name><surname>Kappeler</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Role of SEC24 isoforms in selective export of membrane proteins from the endoplasmic reticulum</article-title><source>EMBO Reports</source><volume>8</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400893</pub-id><pub-id pub-id-type="pmid">17255961</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Gordillo</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>QA</given-names></name><name><surname>Shao</surname><given-names>M</given-names></name><name><surname>Morley</surname><given-names>TS</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Stahl</surname><given-names>A</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Adiponectin is essential for lipid homeostasis and survival under insulin deficiency and promotes β-cell regeneration</article-title><source>eLife</source><volume>3</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.03851</pub-id><pub-id pub-id-type="pmid">25339419</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Garcia</surname><given-names>MR</given-names></name><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Ank</surname><given-names>RS</given-names></name><name><surname>Nam</surname><given-names>AS</given-names></name><name><surname>Fisher</surname><given-names>LW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Surf4 (erv29p) binds amino-terminal tripeptide motifs of soluble cargo proteins with different affinities, enabling prioritization of their exit from the endoplasmic reticulum</article-title><source>PLOS Biology</source><volume>16</volume><elocation-id>e2005140</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2005140</pub-id><pub-id pub-id-type="pmid">30086131</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82269.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schekman</surname><given-names>Randy</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.01.502222" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.01.502222"/></front-stub><body><p>Tang et al. demonstrate that the cargo receptor SURF4 is required for the efficient secretion of PCSK9 and apoB from liver. In its absence, blood cholesterol and triglyceride levels are extremely low. These studies carefully and convincingly demonstrate the in vivo function of SURF4 in liver.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82269.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schekman</surname><given-names>Randy</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Barlowe</surname><given-names>Charles</given-names></name><role>Reviewer</role><aff><institution>Geisel School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Schekman</surname><given-names>Randy</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.01.502222">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.08.01.502222v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Hepatic inactivation of murine <italic>Surf4</italic> results in marked reduction in plasma cholesterol&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Randy Schekman as Reviewing Editor and Reviewer #3, and the evaluation has been overseen by Anna Akhmanova as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Charles Barlowe (Reviewer #2);</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission. The reviewers had a general concern about the overlap of your findings and those reported by your co-author in a publication last year by X. Wang et al. Nonetheless, you have appropriately cited this work and the new results on PCSK9 secretion and the hepatic accumulation of LDLR in the Surf4 fl/fl Alb-Cre+ strain is considered a valuable addition meriting publication of this report as an Advance on your previous <italic>eLife</italic> publications on this topic.</p><p>Essential revisions:</p><p>Reviewers #1 and 2 have several recommendations for small changes that you should be able to accommodate with no additional experimental effort.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Tang et al., in this report investigate the effects of deleting Surf4 in mouse liver. Previously this group has shown that Surf4 functions as a cargo receptor that facilitates the secretion of PCSK9 in cultured cells. Here they have deleted the gene in hepatocytes and find that there is a significant reduction in plasma PCSK9 levels with a resulting increase in LDLR protein and lowering of plasma cholesterol levels. Surf deletion in hepatocytes using albumin-Cre had no deleterious effects in liver. What was found was a 60% reduction in plasma PCSK9 with no change in PCSK9 mRNA levels. These results were confirmed using Cas9 mice in which Surf4 was acutely deleted. Consistent with the known function of PCSK9, the reduction in plasma PCSK9 was associated with a significant increased in liver LDLR protein levels. In addition to dramatically lower plasma cholesterol levels in all lipoprotein fractions, they also find reduced plasma TG levels they show was due to a marked reduction in apoB and TG secretion. Interestingly, there was no defect in intestinal lipid absorption.</p><p>1. Page 7. Humans heterozygous for loss-of-function PCSK9 mutations have ~28% reduction in plasma LDL cholesterol.</p><p>2. Surf4 deletion actually did not result in lipid accumulation in liver as TG levels were not different that controls. This is interesting given the marked reduction in TG secretion and the fact that apoB or MTTP mutations result in significant hepatic steatosis. Is this due to reduced fatty acid and triglyceride synthesis as suggested possibly by RNA seq? If so-what led to this reduced gene expression? To this reviewer's knowledge, this reduction is not observed in apoB or MTTP knockout mice.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Suggest adding information in the methods section that fully describes housing conditions and diet for mice in this study including light/dark cycle if used and composition of chow diet.</p><p>2. Recommend including the full data set of mRNA sequencing data from Figure 5F. Ideally this could be an excel file in the supplement. There may be some changes in mRNA levels that are borderline and would be useful to other investigators. Moreover, in the results and Discussion sections it is mentioned that mRNA levels for genes involved in the UPR and for LDLR expression were not upregulated in Surf4 deficient mice. Presumably this data is contained in the RNA-seq results.</p><p>3. The Figure 3 legend on page 28 is confusing. It is stated that &quot;Accumulation of endo H sensitive SURF4 suggests accumulation in the ER.&quot; Recommend changing this to &quot;Accumulation of endo H sensitive APOB in in the absence of SURF4 suggests accumulation in the ER.&quot;</p><p>4. Molecular weight markers should be added to immunoblots shown in Figures 2, 3, and S5. Presumably the blot in Figure 3B is detecting ApoB-100.</p><p>5. Figure S5 shows an immunoblot using anti-Surf4 antibodies although the source of these antibodies was not described and suggest including in the methods section.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Tang et al., have created a Surf4 fl/fl Alb-Cre+ strain of mice that has allowed the evaluation of liver specific, developmental effects of the deletion of the SURF4 gene on the secretion of PCSK9 and of lipoproteins, cholesterol and triglycerides. This study continues a line of investigation initiated in the Ginsburg lab that led to the discovery that SURF4 is the ER sorting receptor for PCSK9, the plasma protein involved in regulating the itinerary of the LDL receptor (Chen, X et al., 2013 and Emmer et al., 2018). This manuscript was submitted as an Advance on the most recent paper in this series where the team has now shown that SURF4 is required for optimal secretion of PCSK9 in vivo. This work challenges a recent publication by B. Wang et al., (2021) where the claim is made that liver specific deletion of SURF has no effect on the secretion of PCSK9. The differences between the strain developed for this work and that created by for the work of B. Wang et al., is not obvious and the explanation offered by Tang et al., for the difference would be hard to check. Nonetheless, Tang et al., compared their results with another approach that was described last year by X. Wang et al., and the outcome was also a reduction in the level of plasma PCSK9. Thus by two different approaches, the authors find a consistent role for SURF4 in the secretion of PCSK9 in vivo.</p><p>In another important result, Tang et al., show an increase in the level of the liver LDLR in the SURF4 liver specific knockout. This result conforms to the published observations that PCSK9 enhances the down regulation and turnover of the LDLR in cultured cells.</p><p>In other significant results, Tang et al., report a dramatic reduction in plasma cholesterol and triglycerides and an equally impressive decline in the secretion of liver lipoproteins in the null strain.</p><p>The results and conclusions are sound and certainly add confidence to the conclusion that SURF4 is important in the secretion of PCSK9 in vivo. On the down side, this work duplicates much of the important work and results of several of the co-authors who published many of these findings last year (X. Wang et al.) Using an acute deletion of SURF4 in the adult liver, X. Wang et al., already reported a dramatic reduction in plasma cholesterol and triglycerides and a substantial block in the secretion of LDL, HDL, VLDL, APOB and APOA1.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82269.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Tang et al., in this report investigate the effects of deleting Surf4 in mouse liver. Previously this group has shown that Surf4 functions as a cargo receptor that facilitates the secretion of PCSK9 in cultured cells. Here they have deleted the gene in hepatocytes and find that there is a significant reduction in plasma PCSK9 levels with a resulting increase in LDLR protein and lowering of plasma cholesterol levels. Surf deletion in hepatocytes using albumin-Cre had no deleterious effects in liver. What was found was a 60% reduction in plasma PCSK9 with no change in PCSK9 mRNA levels. These results were confirmed using Cas9 mice in which Surf4 was acutely deleted. Consistent with the known function of PCSK9, the reduction in plasma PCSK9 was associated with a significant increased in liver LDLR protein levels. In addition to dramatically lower plasma cholesterol levels in all lipoprotein fractions, they also find reduced plasma TG levels they show was due to a marked reduction in apoB and TG secretion. Interestingly, there was no defect in intestinal lipid absorption.</p><p>1. Page 7. Humans heterozygous for loss-of-function PCSK9 mutations have ~28% reduction in plasma LDL cholesterol.</p></disp-quote><p>We thank the reviewer for raising this point. There are multiple figures reported in the literature and we have edited the text to 28-40% reduction in plasma LDL cholesterol and cited a recent review paper by experts in the field (Cohen and Hobbs, 2013).</p><disp-quote content-type="editor-comment"><p>2. Surf4 deletion actually did not result in lipid accumulation in liver as TG levels were not different that controls. This is interesting given the marked reduction in TG secretion and the fact that apoB or MTTP mutations result in significant hepatic steatosis. Is this due to reduced fatty acid and triglyceride synthesis as suggested possibly by RNA seq? If so-what led to this reduced gene expression? To this reviewer's knowledge, this reduction is not observed in apoB or MTTP knockout mice.</p></disp-quote><p>While levels of triglycerides, along with cholesterol, phospholipids, and free fatty acid were not depleted in Surf4(fl/fl) Alb-Cre(+) mice (figure 5C), we did notice an slight increase in liver lipid content in these mice as demonstrated by two independent methods (EchoMRI and Folch’s lipid extraction from the tissue). At the moment, we do not know the identities of these lipid species. A comprehensive lipidomic study would be needed to answer this question, which we hope the reviewer and editors would agree is beyond the scope of the current manuscript. Additionally, we now note in the text that the mice used in this study are relatively young (3-4 months old) and it is possible that hepatic steatosis might develop in older mice.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Suggest adding information in the methods section that fully describes housing conditions and diet for mice in this study including light/dark cycle if used and composition of chow diet.</p></disp-quote><p>We thank the reviewer for raising this point. We have added housing conditions and diet information to the text (page 12).</p><disp-quote content-type="editor-comment"><p>2. Recommend including the full data set of mRNA sequencing data from Figure 5F. Ideally this could be an excel file in the supplement. There may be some changes in mRNA levels that are borderline and would be useful to other investigators. Moreover, in the results and Discussion sections it is mentioned that mRNA levels for genes involved in the UPR and for LDLR expression were not upregulated in Surf4 deficient mice. Presumably this data is contained in the RNA-seq results.</p></disp-quote><p>We have included an excel file with the full results for the RNA-seq data. Additionally, we have now deposited the raw sequencing files to the GEO.</p><disp-quote content-type="editor-comment"><p>3. The Figure 3 legend on page 28 is confusing. It is stated that &quot;Accumulation of endo H sensitive SURF4 suggests accumulation in the ER.&quot; Recommend changing this to &quot;Accumulation of endo H sensitive APOB in in the absence of SURF4 suggests accumulation in the ER.&quot;</p></disp-quote><p>We thank the reviewer for catching this error. We have edited the figure legend text as suggested (page 29).</p><disp-quote content-type="editor-comment"><p>4. Molecular weight markers should be added to immunoblots shown in Figures 2, 3, and S5. Presumably the blot in Figure 3B is detecting ApoB-100.</p></disp-quote><p>We have added molecular weight markers to the blots in Figure 2 and 3 as suggested. The antibodies used in Figure S5 have previously been validated so MW markers were not included when the blots were run.</p><disp-quote content-type="editor-comment"><p>5. Figure S5 shows an immunoblot using anti-Surf4 antibodies although the source of these antibodies was not described and suggest including in the methods section.</p></disp-quote><p>The antibody against SURF4 was previously generated as described in X. Wang et al., 2021. We have included this information and the sources for other antibodies used in the method section (page 15 and 16).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Tang et al., have created a Surf4 fl/fl Alb-Cre+ strain of mice that has allowed the evaluation of liver specific, developmental effects of the deletion of the SURF4 gene on the secretion of PCSK9 and of lipoproteins, cholesterol and triglycerides. This study continues a line of investigation initiated in the Ginsburg lab that led to the discovery that SURF4 is the ER sorting receptor for PCSK9, the plasma protein involved in regulating the itinerary of the LDL receptor (Chen, X et al., 2013 and Emmer et al., 2018). This manuscript was submitted as an Advance on the most recent paper in this series where the team has now shown that SURF4 is required for optimal secretion of PCSK9 in vivo. This work challenges a recent publication by B. Wang et al., (2021) where the claim is made that liver specific deletion of SURF has no effect on the secretion of PCSK9. The differences between the strain developed for this work and that created by for the work of B. Wang et al., is not obvious and the explanation offered by Tang et al., for the difference would be hard to check. Nonetheless, Tang et al., compared their results with another approach that was described last year by X. Wang et al., and the outcome was also a reduction in the level of plasma PCSK9. Thus by two different approaches, the authors find a consistent role for SURF4 in the secretion of PCSK9 in vivo.</p><p>In another important result, Tang et al., show an increase in the level of the liver LDLR in the SURF4 liver specific knockout. This result conforms to the published observations that PCSK9 enhances the down regulation and turnover of the LDLR in cultured cells.</p><p>In other significant results, Tang et al., report a dramatic reduction in plasma cholesterol and triglycerides and an equally impressive decline in the secretion of liver lipoproteins in the null strain.</p><p>The results and conclusions are sound and certainly add confidence to the conclusion that SURF4 is important in the secretion of PCSK9 in vivo. On the down side, this work duplicates much of the important work and results of several of the co-authors who published many of these findings last year (X. Wang et al.) Using an acute deletion of SURF4 in the adult liver, X. Wang et al., already reported a dramatic reduction in plasma cholesterol and triglycerides and a substantial block in the secretion of LDL, HDL, VLDL, APOB and APOA1.</p></disp-quote><p>We thank the reviewer for the critiques. We acknowledge that the hypocholesterolemia phenotype in hepatic SURF4 deficient mice and the roles of SURF4 in the secretions of several lipoproteins have been reported by some of the co-authors (X. Wang et al). Our work add confidence to these findings using a different genetic model (embryonic liver-specific deletion). Further, while the findings in siRNA mediated hepatic <italic>Surf4</italic> knockdown mice were similar to those seen in mice with acute liver SURF4 deletion; they were different approaches. Together, we demonstrated the roles of SURF4 in the liver using three separate mouse models, which we hope provides important validation for the previous studies, as well as valuable new data.</p></body></sub-article></article>